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THE CATIONIC PEPTIDES OF NATURE 
No therapeutically useful new classes of antibiotics have 
been identified in the past quarter of a century This 
has become of major consequence in the face of the 
increase in the incidence of significant antibiotic 
resistance in the past decade. Indeed, strains of several 
important pathogens have been identified for which 
very few, or even no, possibilities for antibiotic therapy 
exist. Although several broad-spectrum improved 
variants of existing antibiotic classes have been pro- 
duced (e.g. new fluoroquinolones, imipenem), it seems 
that bacteria can relatively easily become resistant to 
these by modulation of known resistance mechanisms. 
For this reason there is great interest in identifying 
novel antibiotic classes with potential in human thera- 
peutics. 
Human beings and other species are continually 
exposed to numerous bacteria. Even in the absence of 
an immune response, they rarely become infected 
because of the potency of their so-called non-specific 
defenses. Thus, it is worth looking to these defenses as 
a potential source of new antimicrobial strategies. In the 
past decade it has become apparent that many organ- 
isms use cationic peptides as a major non-specific 
defense against infections (Table 1). Indeed, more 
than 140 cationic peptides are known, having been 
identified in nearly every species of life [l]. In plants 
(e.g. thionins) and insects (e.g. cecropins and insect 
defensins), cationic peptides provide the predominant 
mechanism of defense against bacteria and fungi. In 
insects, such peptides are inducible by mechanisms that 
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closely resemble immune response regulation [2]. 
Among aniphibians, cationic peptides (eg. magainins) 
constitute the major protection for the skins of frogs 
and toads, which almost never become infected, despite 
their exposure to enormous numbers of potential 
pathogens. In higher animals, including humans, 
cationic peptides (e.g. defensins) are the major protein 
species (-8-15% of total proteins) in neutrophils, which 
are the most important cells in the non-specific defense 
of the body against invasive pathogens. In addition, 
other cationic peptides are found in high concen- 
trations at  niucosal surfaces; for example, lingual 
antimicrobial peptide, tracheal antimicrobial peptide 
and cecropin P1 are considered by some to contribute 
significantly to mucosal immunity [3].  Cationic 
peptides are also produced by bacteria, fungi and 
crustaceans. Thus they can truly be described ubiqui- 
tous. This brief review presents an overview of the 
cationic peptides. For more details, the reader is 
referred to our more extensive review [l]. 
THE NATURE OF CATIONIC PEPTIDES 
Cationic peptides are perhaps the finest example of 
convergent evolution, in which diverse molecules have 
Table 1 Examples of antimicrobial peptides found in 
nature 
Source Exaniule Structural motifs 
Mammalian neutrophils Defensins 3 P-strands 
3 disulphidrs 
Amphibian skin Magainins Amphipathic 
a-helix 
Insect hernolymph Cecropim Amphipathic 
a-helix 
Crustace~ris Tachyplesins 2 P-strands 
2 disulphides 
Plants Thionins 3 disulphidrs 
Structure unknown 
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Magainin-2 
Figure 1 Helical wheel diagram (axial projection) for 
magainin-’, demonstratiiig the ainphipathic nature of the 
a-helix. This dernonstrdtes that one side of the a-helix is 
quite hydrophobic (solid circles) whereas the other contains 
most o f  the hydrophilic residuec, including the five 
clustered lysine (K) residues (open circles), A single-letter 
code is used for amino acids. Reproduced by copyright 
permission from Kini and Evans [23] 0 International 
Journal of Peptide and Protein Research. 
evolved towards a coninion function: the ability to  kill 
infectious microbes. However, it is clear that the 
differences between the peptides with this common 
function are as profound as the similarities. All cationic 
peptides consist of sequences of between 12 and about 
40 amino acids. These sequences usually contain two 
to six positively charged amino acids (lysine or  
arginine) and rarely more than one negatively charged 
amino acid. Another similarity is that such molecules 
can fold in three dimensions, under the appropriate 
conditions, which usually involve incorporation in  a 
membrane, to  present a hydrophobic face and a 
hydrophilic face (Figure 1), the latter of which contains 
the charged amino acids. Within this coninion struc- 
ture, however, many variations exist. For example, the 
uncharged amino acids are usually restricted to a subset 
o f  amino acids, but the identity of the specific amino 
acids from this subset varies substantially from species 
to  species. In addition, unusual amino acids (e.g. 
laiithionine) are often found i n  bacterial cationic 
peptides (e.g. nisin), and modified C- and N-terminal 
amino acids are also quite common. More importantly, 
the secondary and tertiary structures of  the peptides can 
vary, including P-structured peptides with strands 
stabilized by disulfide bridges [4,5], a-helices [6,7] and 
more extended structures (Hancock and Falla, un- 
published). T h e  four general classes of cationic peptides 
recognized in  the literature are P-structured peptides, 
a-helical peptides, loop structures created by a cysteine 
disulfide bridge and peptides with a predominance of  a 
single aniino acid (Trp, Pro or  His). 
ANTIMICROBIAL ACTIVITIES 
T h e  spectrum of  antimicrobial activity of  cationic 
peptides varies, to include broad-spectrum antibacterial 
activity, selectivity for either Gram-negative or  G r a n -  
positive bacteria, and antifungal action 111. Table 2 
presents the minimal inhibitory concentrations (MICs) 
of  selected cationic peptide variants, compared with 
their parent peptides from natural sources and with 
some conventional antibiotics. While not as potent as 
the classical antibiotics against the most susceptible 
microorganisms, these cationic peptides have certain 
apparent advantages. First, they have quite consistent 
activities against both antibiotic-susceptible and clini- 
cally antibiotic-resistant variants of a given antimicro- 
bial species (e.g. niethicillin-resistant Staphylococcus 
aureus, niultiresistant Pseudomonas aevuginorn and Entero- 
bacter cloacae). Second, they d o  not seem to select 
resistant mutants even after multiple passages on media 
containing the peptide at a concentration of half the 
MIC. Third, they kill very rapidly at the MIC,  with 
more than 99.9% of  bacteria killed within 20 niin [S] 
and probably within 2 min (Falla and Hancock, 
unpublished data), whereas niost conventional anti- 
biotics kill less than 90% of bacteria within 60 niin at 
the MIC.  Studies on  intraperitoneal I? aevugiuosa 
infections of  neutropenic mice have clearly demon- 
strated a therapeutic effect of cationic peptide applica- 
tion, even when only a single dose is applied 191. 
Furthermore, the conipany Applied Microbiology Inc. 
has reported briefly on a protective effect against 
infections by Helicobactcr spp. in mice. 
It must be stated that the above MICs are increased 
in  the presence of high concentrations of  divalent 
cations. Although this may reflect, in part, competition 
for bacterial surface binding sites, our recent experi- 
ments indicate that there may be a more trivial 
explanation for this phenomenon, and we are currently 
attempting to define this more fully. 
Table 2 MICv of selected cationic peptide variants arid 
antibiotics data selected from Pier5 et a1 [XI  
MIC (ing/L) 
Spccirs Melittin CEME CEMA I’X G M  
Ercherirhia roli 8 2.4 2.8 0.5 I 
Pseirdo~nuriar aerucyinosa 8 2.4 2.8 0.5 1 
Salmorzella typlplzi~nitriim 16 2.4 5.6 1 4 
Enterohatter cloacae 8 2.4 2.8 0.5 0.5 
‘PX = polyniyxin B; GM = gentaniiciii 
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In addition to direct antimicrobial activity, cationic 
peptides have two other usefd activities against 
bacteria. First, they can act as ‘enhancers’ of conven- 
tional antibiotics by showing synergy in vitro with such 
antibiotics. The cationic peptide polyniyxin B nona- 
peptide has been well characterized with respect to this 
property [lo]. Also, clear synergy has been demon- 
strated between the peptide niagainin and cefpirome in 
a mouse infection model, even though the magainin 
was ineffective by itself [ll].  Second, unlike some 
conventional antibiotics which release endotoxin from 
bacteria and contribute to the development of endo- 
toxemia, cationic peptides actually bind endotoxin and 
prevent it from inducing tumor necrosis factor, and 
they substantially reduce endotoxic shock in galacto- 
samine-sensitized mice [9]. 
OTHER ACTIVITIES OF CATIONIC PEPTIDES 
Numerous other activities have been demonstrated 
for individual cationic peptides. These include activity 
against pathogenic protozoa 112,131 and enveloped 
viruses [14], anticancer activity [15], antiprotease 
activity [16], a role in insect development [17], and an 
ability to promote re-epithelialization of damaged 
tissues. 
PRODUCTION 
Despite the relatively high levels of cationic peptides 
within specific tissues, it is impractical to use such 
natural sources for high-level production. More 
commonly protein chemical methods are used for 
synthesis. However, even using the most refined new 
methods of peptide synthesis (solution-phase chemistry), 
it is quite expensive to produce peptides by this route, 
and this may limit potential clinical usage. An 
interesting possibility is provided by recombinant DNA 
technology, in which the peptides are produced as parts 
of fusion proteins encoded by plasmids. This method 
[lS] can be used to produce virtually any cationic 
peptide sequence in quite high yields (approximately 
2% of bacterial cell biomass) using the classical 
methodology of bacterial fermentation. We believe that 
this method will yield peptides in large enough 
amounts, and inexpensively enough, to make clinical 
use practicable. 
MODE OF ACTION 
The actual mechanism of bacterial killing by cationic 
peptides involves the formation of channels in the 
cytoplasmic membranes of the target bacteria 111. 
Model membrane studies have suggested that such 
channels are of two types, multistate channels, in which 
different numbers of peptides participate in forming 
individual channels (more subunits = bigger channels), 
and channels of defined size, which presumably involve 
some energetically favored number of subunits in a 
fixed arrangement [ 19,201. For example, two niolecular 
models for channel formation by cecropin have been 
proposed by Durell et a1 [20]. These contain the 
arrangement of six dimers in star and circular con- 
formations, producing channel sizes consistent with 
two experimental conductance increments observed by 
Christensen et a1 [21]. Bacterial cells are then killed 
because of the leakage of ions and essential chemicals 
from the cell. Some features of channel formation 
suggest the basis for peptide selectivity, in that channel 
formation requires a high transnieinbrane potential of 
greater than -80 mV and is inhibited by the presence 
of cholesterol in membranes. Thus bacterial cyto- 
plasmic membranes, being cholesterol-free and having 
a high transmembrane electrical potential gradient (of 
-140 niV), are favored for peptide insertion, whereas 
eukaryotic cell membranes having a low gradient 
(- 15 mV or so) and including cholesterol are not. 
The above process occurs in both Gram-positive 
and Gram-negative bacteria. However, an additional 
interaction must occur in Gram-negative bacteria, i.e. 
with the outer membrane. We have provided sub- 
stantial data [8] to indicate that the mechanism utilized 
by cationic peptides to cross the outer membrane is self- 
pronioted uptake. In this mechanism the cationic 
peptides physically interact with divalent-cation-binding 
sites on surface lipopolysaccharide and, being bulkier 
than the divalent cations they displace, cause a 
perturbation of the outer membrane through which 
uptake of other cationic peptide molecules is pro- 
moted. This mechanism explains two of the other 
antibacterial activities of cationic peptides, namely 
enhancer and anti-endotoxin activities. Presumably 
those peptides that are selective for Gram-negative 
bacteria (e.g. cecropins) have their activities actually 
enhanced by this primary interaction. 
CLINICAL CONSIDERATIONS 
Every antibiotic introduced into clinical use faces three 
major issues besides efficacy, namely formulation, 
toxicity and stability. To date only topical usage of these 
peptides has been attempted. The first clinical trials of 
MSI-78 against impetigo failed, probably because of 
poor clinical trial design (75% cure in the mock-treated 
controls), but the second clinical trial against diabetic 
foot ulcer has been claimed by the company Magainin 
Sciences to demonstrate equivalent efficacy to quino- 
lones. Clearly, the successful passage of peptides into 
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phase 111 clinical trials suggests that the three major 
concerns described above have been solved for topical 
usage. However, such usage does not seem to play to 
the strengths of cationic peptide antibiotics and it is 
more interesting to consider systemic or organ-specific 
therapy. With regard to formulation, not much is 
known. The few published animal trials have largely 
involved delivery of the cationic peptides in saline 
19,11]. An alternative approach is liposornal formula- 
tion, which has been shown to improve the bioavail- 
ability and activity in vivo of the peptide indolicidin 
The issue of toxicity is a serious one, since there 
are known cationic peptides which are potent toxins 
(e.g. melittin, the major toxic component of bee 
venom). There is very little information about the 
known cationic peptides, although our own experiences 
to date show no toxic effects on macrophage tissue- 
culture cells, and no obvious toxicity a t  the highest 
doses in our animal models. Stability is a major issue, 
too, since proteases abound in the body. Decpite these 
considerations, we feel that cationic peptides offer 
exciting prospects as clinical agents and real potential as 
the first breakthrough class of antibiotics in 25 years. 
[22]. 
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